Mizuho: these two biotech stocks are worth buying right now | Invezz
Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Wajeeh Khan
on
May 9, 2022
The Mizuho analyst explains why Cytokinetics is a buy right now.
The SPDR S&P Biotech ETF is now down about 45% year-to-date.
Biotech is one of the hardest hit sectors this year, with the SPDR S&P Biotech ETF now down 45% year-to-date. Still, a Mizuho analyst says the following two stocks are worth buying.
Syed sees significant upside in Gilead Sciences
A large cap name that pops out to Selim Syed in biotech is Gilead Sciences Inc (NASDAQ: GILD), down roughly 15% year-to-date. Speaking with CNBC’s Brian Sullivan on Monday, he said:
Are you looking for fast-news, hot-tips and market analysis?
Sign-up for the Invezz newsletter, today.
Gilead trades close to our DCF values. It’s currently the best in class on a free cash flow yield basis. So, we like it primarily on valuation, but it’s hard to pinpoint what catalyst will get this stock going.
Syed has a price target of $75 a share on Gilead Sciences that represents a more than 20% upside from here. A week ago, GILD reported market-beating results for its fiscal Q1.
Syed’s favourite small-cap biotech stock
A biotech stock that the Mizuho analyst likes more than Gilead Sciences, however, is the California-based small cap, Cytokinetics Inc (NASDAQ: CYTK). On CNBC’s “Worldwide Exchange”, Syed noted:
Cytokinetics has a drug for a cardiovascular disease. It trades at about $3.50 billion. The clinical data so far seems to support valuation that could be much higher than where it’s currently trading.
CYTK is down nearly 25% versus the start of the year. In late 2020, Bristol Myers Squibb bought a similar clinical stage biopharmaceutical company, MyoKardia, for $13 billion.
eToro
10/10
68% of retail CFD accounts lose money
Visit site
Biotech
ETFs
Health & pharmaceuticals
Industries
North America
Stocks & Shares
Technology
USA
World
